LONDON – GenKyoTex has begun initial prospecting for commercialization partners as its first-in-class dual NOX inhibitor, GKT137831, enters Phase I trials, and academic collaborators deliver further evidence of the drug's therapeutic effect in models of diabetic nephropathy.